<ARTICLE> 5 <LEGEND> THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE FINANCIAL STATEMENTS OF RIBOZYME PHARMACEUTICALS, INC. FOR THE SIX MONTHS ENDED JUNE 30, 1999 AND IS QUALIFED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS. </LEGEND> <PERIOD-TYPE> 6-MOS <FISCAL-YEAR-END> DEC-31-1999 <PERIOD-START> JAN-01-1999 <PERIOD-END> JUN-30-1999 <CASH> 11,264,609 <SECURITIES> 1,000,136 <RECEIVABLES> 2,593,937 <ALLOWANCES> 0 <INVENTORY> 0 <CURRENT-ASSETS> 15,385,818 <PP&E> 11,734,110 <DEPRECIATION> 7,669,307 <TOTAL-ASSETS> 23,246,486 <CURRENT-LIABILITIES> 1,813,822 <BONDS> 0 <PREFERRED-MANDATORY> 0 <PREFERRED> 0 <COMMON> 92,279 <OTHER-SE> 13,313,846 <TOTAL-LIABILITY-AND-EQUITY> 23,246,486 <SALES> 0 <TOTAL-REVENUES> 3,876,973 <CGS> 0 <TOTAL-COSTS> 0 <OTHER-EXPENSES> 7,385,123 <LOSS-PROVISION> 0 <INTEREST-EXPENSE> 261,308 <INCOME-PRETAX> (5,361,182) <INCOME-TAX> 0 <INCOME-CONTINUING> (5,361,182) <DISCONTINUED> 0 <EXTRAORDINARY> 0 <CHANGES> 0 <NET-INCOME> (5,361,182) <EPS-BASIC> (0.58) <EPS-DILUTED> (0.58)